Spotlight series: Pivotal trials through today's knowledge - Adrenocorticotrophic hormone

International MS Journal

Volumn 16, Issue 2, 2009, Pages 42-46

  Sibley, William A ^a  

^a UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Adrenocorticotrophic hormone and multiple sclerosis; History of multiple sclerosis treatment; Randomized controlled trials

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; CORTISONE; GLUCOCORTICOID; METHYLPREDNISOLONE; PLACEBO; HORMONE;

BLOOD BRAIN BARRIER; CATARACT; CLINICAL RESEARCH; CLINICAL TRIAL; COMPRESSION FRACTURE; CONTROLLED CLINICAL TRIAL; DIFFUSION WEIGHTED IMAGING; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GASTROINTESTINAL HEMORRHAGE; HUMAN; HYPERADRENOCORTICISM; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ADRENOCORTICOTROPIC HORMONE; HORMONES; HUMANS; MULTIPLE SCLEROSIS;

EID: 70349770120     PISSN: 13528963     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (33)

1. Sibley WA: Drug treatment of multiple sclerosis. In: Handbook of Clinical Neurology, Multiple Sclerosis and Other Demyelinating Diseases, Vol. XIII (Vinken PJ, Bruyn GW, eds). Amsterdam: North-Holland Publishing Co. 1970; pp383-407.
2. Schumacher GA, Beebe G, Kibler RF, Kurlund LT, Kurtzke JF, McDowell F et al. Problems of experimental trials of therapy in multiple sclerosis: report by the panel on the evaluation of experimental trials of therapy in multiple sclerosis. Ann NY Acad Sci 1965; 122: 552-568.
3. Kurtzke JF. On the evaluation of disability in multiple sclerosis. Neurology 1961; 11: 686-694.
4. Tourtellotte WW, Haerer AF, Simpson JF, Kuzma JW, Sikorski J. Quantitative neurological testing. I. A study of a battery of tests designed to evaluate in part the neurological function of patients with multiple sclerosis and its use in a therapeutic trial. Ann NY Acad Sci 1965; 122: 480-487.
5. Adams CW. Inflammatory vasculitis in multiple sclerosis. J Neurol Sci 1985; 69: 269-283.
6. Miller H, Newell DJ, Ridley A. Multiple sclerosis. Treatment of acute exacerbations with corticotrophin (ACTH). Lancet 1961; 2(7212): 1120-1122.
7. Miller H. Discussion. In: Rose AS, Kuzma JW, Kurtzke JF, Sibley WA, Tourtellotte WW. Cooperative study in evaluation of therapy in multiple sclerosis: ACTH vs placebo in acute exacerbations. Trans Am Neurol Assn 1969; 94: 126-133.
8. Rose AS, Kuzma JW, Kurtzke JF, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo in acute exacerbations. Preliminary report. Neurology 1968; 18(Suppl): 1-10.
9. Rose AS, Kuzma JW, Kurtzke JF, Sibley WA, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs placebo -final report. Neurology 1970; 20: 1-59.
10. Jonsson B, Von Reis G, Sahlgren E. Experience of ACTH and cortisone treatment in some organic neurological cases. Acta Psychiatr Neurol Scand 1951; 74: 60-65.
11. Barnes MP, Bateman DE, Cleland PG, Dick DJ, Walls TJ, Newman PK et al. Intravenous methylprednisolone for multiple sclerosis in relapse. J Neurol Neurosurg Psychiatry 1985: 48: 157-159.
12. Thompson AJ, Kennard C, Swash M, Summers B et al. Relative efficacy of intravenous methylprednisolone and ACTH in the treatment of acute relapse in MS. Neurology 1989; 39: 969-971.
13. Milligan NM, Newcombe R, Compston DA. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis. 1. Clinical effects. J Neurol Neurosurg Psychiatry 1987; 50: 511-516.
14. Schimmer BP, Parker KL. ACTH, adrenocortical steroids and their synthetic analogs. In: Goodman & Gilman's The Pharmacologic Basis of Therapeutics (Hardman JG, Limbird LE, eds). London/New York: McGraw Hill 2001; pp1649-1677.
15. Davis FA, Stefoski D. Is steroid therapy in multiple sclerosis superior to corticotrophin therapy? Arch Neurol 1988; 45: 1180 (Letter).
16. Poser CM. Coricotropin is superior to corticosteroids in the treatment of MS. Arch Neurol 1989; 46: 946.
17. Merritt HH, Glaser GH, Herrmann C. A study of the short- and long-term effects of adrenal steroids on the clinical course of multiple sclerosis. Ann NY Acad Sci 1954; 58: 625-629.
18. Optic Neuritis Study Group. Visual function 5 years after optic neuritis; experience of the Optic Neuritis Treatment Trial. Arch Ophthalmol 1997; 115: 1545-1552.
19. Cass LJ, Alexander L, Enders M. Complications of corticotrophin therapy in multiple sclerosis. JAMA 1966; 197: 173-178.
20. Pirko I, Rodriguez M. Pulsed intravenous methylprednisolone therapy in progressive multiple sclerosis: need for a controlled trial. Arch Neurol 2004; 61: 1148-1149.
21. Uttner I, Muller S, Zinser C, Maier M, Sussmuth S, Claus A et al. Reversible impaired memory induced by pulsed methylprednisolone in patients with MS. Neurology 2005; 64: 1971-1973.
22. Ciccone A, Beretta S, Brusaferri F, Galea I, Protti A, Spreafico C. Corticosteroids for the long-term treatment in multiple sclerosis. Cochrane Database Syst Rev 2008; Jan. 23: CD006264.
23. National Multiple Sclerosis Society. Expert Opinion Paper. Recommendations regarding corticosteroids in the management of multiple sclerosis. Available at: http//www.nationalmssociety.org/forprofessionals/ healthcareprofessionals/publications/expertopinionpapers/download.aspx?id=553. Accessed 16 April 2008.
24. Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-1247.
25. Goodkin DE, Kinkel RP, Weinstock-Guttman B, VanderBrug-Medendorp S, Secic M, Gogol D et al. A phase II study of IV methylprednisolone in secondary progressive multiple sclerosis. Neurology 1998; 51: 239-245.
26. Kermode AG, Tofts PS, Thompson AJ, MacManus DG, Rudge P, Kendall BE et al. Heterogeneity of blood-brain barrier changes in multiple sclerosis: an MRI study with gadolinium-DTPA enhancement. Neurology 1990; 40: 229-235.
27. Werring DJ, Brassat D, Droogan AG, Clark CA, Symms MR, Barker GJ et al. The pathogenesis of lesion and normal-appearing white matter changes in multiple sclerosis: a serial diffusion MRI study. Brain 2000; 123: 1667-1676.
28. Filippi M, Rocca MA, Martino G, Horsfield MA, Comi G. Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 1998; 43: 809-814.
29. Hansen T, Skytthe A, Stenager E, Petersen HC, Brennum-Hansen H, Kyvik KO. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler 2005; 5: 504-510.
30. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC; Canadian Collaborative Study Group. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A 2003; 100: 12877-12882.
31. Sibley WA, Bamford CR, Clark K. Clinical viral infections and multiple sclerosis. Lancet 1985; 1: 1313-1315.
32. Sibley WA. The effect of viruslike infections on the course of multiple sclerosis. In: Genes and Viruses in Multiple Sclerosis (Hommes OR, Clanet M, Wekerle H, eds). Amsterdam/ New York: Elsevier 2001; pp89-95.
33. Kriesel JD, Sibley WA. The case for rhinoviruses in the pathogenesis of multiple sclerosis. Editorial. Mult Scler 2005; 11: 1-4.